One plus one equals four

Karus' KA2237 parlays two targets into four antitumor mechanisms

Karus Therapeutics Ltd. thinks its lead compound KA2237 can leverage two targets to kick off twice as many antitumor mechanisms, and create a therapeutic index large enough for drug combinations. First dosed in B cell lymphoma patients this month, the compound - a dual inhibitor of phosphoinositide 3-kinase catalytic subunit β polypeptide (PI3KCB; p110β) and PI3KCD (p110δ)

Read the full 574 word article

User Sign In